StoxSai Life Sciences Ltd.
NSE: SAILIFE · Healthcare
Ask the data
Instant answers about Sai Life Sciences Ltd. — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 2,192 |
| EBITDA | 631 |
| Operating margin | 28.8% |
| Interest | 39 |
| Depreciation | 167 |
| Profit before tax | 466 |
| Tax | 117 |
| Net profit | 349 |
| EPS ₹ | 16.63 |
| Operating cash flow | 509 |
| Capex | 593 |
| Dividend paid | 0 |
| Total assets | 3,626 |
| Equity | 2,484 |
Quarterly performance
last 7 quarters · ₹ crore| DEC '24 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|
| Revenue | 440 | 496 | 537 | 556 | 602 | 554 | 659 |
| Operating profit | 120 | 121 | 146 | 188 | 177 | 148 | 186 |
| Operating margin | 27.2% | 24.4% | 27.1% | 33.8% | 29.3% | 26.7% | 28.3% |
| Other income | 9 | 10 | 15 | 8 | 16 | 4 | 4 |
| Interest | 23 | 12 | 9 | 10 | 8 | 8 | 11 |
| Depreciation | 34 | 38 | 40 | 44 | 45 | 46 | 48 |
| Profit before tax | 72 | 81 | 112 | 134 | 139 | 98 | 131 |
| Tax | 18 | 20 | 28 | 34 | 35 | 25 | 33 |
| Net profit | 0 | 60 | 0 | 0 | 104 | 0 | 98 |
| EPS ₹ | 2.89 | 2.90 | 4.01 | 4.77 | 4.93 | 3.46 | 4.63 |
| Revenue YoY | — | — | — | 26.5% | — | 11.7% | 22.5% |
| Profit YoY | — | — | — | — | — | -100.0% | — |
Returns & margins
trailing-twelve-month, per quarter| MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|
| ROE | 6.6% | 4.2% | 7.5% |
| ROCE | 19.6% | 20.1% | 17.2% |
| Net margin | 7.5% | 4.6% | 8.5% |
| EBITDA margin | 28.8% | 29.2% | 29.5% |
| Debt / equity | 0.04 | 0.04 | 0.17 |
| Interest coverage | 12.88 | 15.00 | 14.92 |
| Asset turnover | 0.60 | 0.62 | 0.56 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|
| Share capital | 21 | 21 | 21 |
| Other equity / reserves | 2,249 | 2,463 | 2,667 |
| Total equity | 2,270 | 2,484 | 2,688 |
| Borrowings | 215 | 95 | 448 |
| Current liabilities | 775 | 834 | 1,185 |
| Non-current liabilities | 286 | 309 | 329 |
| Total assets | 3,332 | 3,626 | 4,202 |
| Property, plant & equipment | 1,613 | 1,809 | 2,028 |
| Capital work-in-progress | 115 | 270 | 560 |
| Investments | 2 | 50 | 52 |
| Inventories | 122 | 151 | 242 |
| Receivables | 492 | 374 | 342 |
| Cash & equivalents | 208 | 82 | 31 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 509 |
| Cash from investing | -395 |
| Cash from financing | -124 |
| Capex | 593 |
| Free cash flow | -84 |
| Dividends paid | 0 |
Where the assets sit
Sep '26 · ₹ crorePeer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Sai Life Sciences Ltd. | 37,919 | 1,785.10 | 187.2 | 14.11 | 7.5% |
StoxGud checklist: Neutral setup · 6/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
Compare Sai Life Sciences Ltd. with
FAQs
What is the share price of Sai Life Sciences Ltd.?
Sai Life Sciences Ltd. (SAILIFE) closed at ₹1,785.10 on NSE on 06 Nov 2026.
What is the market cap of Sai Life Sciences Ltd.?
₹37,919 crore at the latest close.
What is the P/E ratio of Sai Life Sciences Ltd.?
187.2, on trailing-twelve-month earnings from its filings.
How fast is Sai Life Sciences Ltd. growing?
Sai Life Sciences Ltd.: Latest-quarter revenue is up 22.5% year on year.
How profitable is Sai Life Sciences Ltd.?
On a trailing-twelve-month basis return on equity is 7.5%, return on capital employed 17.2%, operating margin 29.5%, net margin 8.5%.
How much debt does Sai Life Sciences Ltd. have?
Sai Life Sciences Ltd. is lightly geared: debt to equity is 0.17 with borrowings of ₹448 cr against cash of ₹31 cr (balance sheet of 2026-09-30). Operating profit covers interest 14.9 times.
Financials parsed from Sai Life Sciences Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from DEC '24, annual from FY26, balance sheet from Sep '25. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.